NO2766039T3 - - Google Patents

Info

Publication number
NO2766039T3
NO2766039T3 NO12769684A NO12769684A NO2766039T3 NO 2766039 T3 NO2766039 T3 NO 2766039T3 NO 12769684 A NO12769684 A NO 12769684A NO 12769684 A NO12769684 A NO 12769684A NO 2766039 T3 NO2766039 T3 NO 2766039T3
Authority
NO
Norway
Application number
NO12769684A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2766039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2766039T3 publication Critical patent/NO2766039T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C19/00—Alloys based on nickel or cobalt
    • C22C19/03—Alloys based on nickel or cobalt based on nickel
    • C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
    • C22C19/058—Alloys based on nickel or cobalt based on nickel with chromium without Mo and W
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D22/00—Shaping without cutting, by stamping, spinning, or deep-drawing
    • B21D22/02—Stamping using rigid devices or tools
    • B21D22/022—Stamping using rigid devices or tools by heating the blank or stamping associated with heat treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21J—FORGING; HAMMERING; PRESSING METAL; RIVETING; FORGE FURNACES
    • B21J1/00—Preparing metal stock or similar ancillary operations prior, during or post forging, e.g. heating or cooling
    • B21J1/06—Heating or cooling methods or arrangements specially adapted for performing forging or pressing operations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C19/00—Alloys based on nickel or cobalt
    • C22C19/03—Alloys based on nickel or cobalt based on nickel
    • C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/10—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO12769684A 2012-07-20 2012-10-10 NO2766039T3 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305889 2012-07-20

Publications (1)

Publication Number Publication Date
NO2766039T3 true NO2766039T3 (en:Method) 2018-04-21

Family

ID=48081395

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12769684A NO2766039T3 (en:Method) 2012-07-20 2012-10-10

Country Status (31)

Country Link
US (2) US10927435B2 (en:Method)
EP (1) EP2766039B1 (en:Method)
JP (5) JP6122018B2 (en:Method)
KR (3) KR20190014117A (en:Method)
CN (2) CN104105505A (en:Method)
AR (1) AR088289A1 (en:Method)
AU (1) AU2012323062B2 (en:Method)
BR (1) BR112014008764A8 (en:Method)
CA (1) CA2851751A1 (en:Method)
CL (1) CL2014000926A1 (en:Method)
CO (1) CO6950482A2 (en:Method)
DK (1) DK2766039T3 (en:Method)
ES (1) ES2660112T3 (en:Method)
HU (1) HUE036561T2 (en:Method)
IL (1) IL232001A0 (en:Method)
LT (1) LT2766039T (en:Method)
MA (1) MA35620B1 (en:Method)
MX (3) MX388710B (en:Method)
MY (1) MY177212A (en:Method)
NO (1) NO2766039T3 (en:Method)
PH (1) PH12014500784B1 (en:Method)
PL (1) PL2766039T3 (en:Method)
PT (1) PT2766039T (en:Method)
RS (1) RS56973B1 (en:Method)
RU (1) RU2664697C2 (en:Method)
SG (3) SG11201401373RA (en:Method)
SI (1) SI2766039T1 (en:Method)
TR (1) TR201802387T4 (en:Method)
TW (1) TWI589299B (en:Method)
UY (1) UY34387A (en:Method)
WO (1) WO2013053751A1 (en:Method)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AU2012210481B2 (en) 2011-01-28 2017-05-18 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to PCSK9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2950796A1 (de) * 2013-01-31 2015-12-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische zusammensetzung umfassend leflunomid
JP6756611B2 (ja) 2013-10-31 2020-09-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 中和抗体を検出するための競合リガンド結合アッセイ
CN120514847A (zh) * 2013-11-22 2025-08-22 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
PT3071230T (pt) * 2013-11-22 2020-06-26 Regeneron Pharma Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
WO2016044343A1 (en) * 2014-09-16 2016-03-24 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR101895950B1 (ko) * 2015-12-18 2018-09-06 (주)한국비엠아이 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법
TW202419103A (zh) * 2016-03-07 2024-05-16 法商賽諾菲生物技術公司 用於治療類風濕性關節炎之組成物及方法
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
CN107456455B (zh) * 2016-06-06 2021-09-24 海南先声药业有限公司 一种预防或治疗炎性疾病的药物组合物
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
KR102798879B1 (ko) 2017-09-19 2025-04-30 리제너론 파아마슈티컬스, 인크. 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
MX2020005699A (es) 2017-12-13 2020-10-16 Regeneron Pharma Dispositivos y sistemas para manipulacion de soportes de lecho de columna para cromatografia y metodos relacionados.
WO2019136219A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating autoimmune disorders with acetylcholinesterase inhibitors
CN108597083A (zh) * 2018-04-28 2018-09-28 江苏食品药品职业技术学院 一种酒店旅游自助服务系统
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
MA52966A (fr) * 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CN109013990A (zh) * 2018-08-04 2018-12-18 安徽盛美金属科技有限公司 一种加热铝合金锻压件坯料的装置
TW202532441A (zh) 2018-08-29 2025-08-16 美商再生元醫藥公司 用來治療患有類風濕性關節炎之個體的方法及組成物
CN109858649A (zh) * 2019-01-04 2019-06-07 珠海格力电器股份有限公司 预订酒店方法和装置、酒店管理方法和装置
TWI860325B (zh) 2019-01-31 2024-11-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
BR112021021077A2 (pt) 2019-04-24 2021-12-14 E Zilberstein Moshe Métodos de diagnóstico e tratamento de artrite reumatoide
WO2020247461A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
KR102453140B1 (ko) 2021-09-07 2022-10-11 배호진 블록체인을 이용한 후원자 보상 방법 및 장치

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
DE122009000023I2 (de) 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
EP0672144A1 (en) 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
CA2201781C (en) 1994-10-07 2010-01-12 Tadamitsu Kishimoto Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component
RU2147442C1 (ru) 1994-10-21 2000-04-20 Кисимото Тадамицу Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6
AU704723B2 (en) 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
ATE330629T1 (de) 1995-02-13 2006-07-15 Chugai Pharmaceutical Co Ltd Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
EP0923941B1 (en) 1996-06-27 2006-05-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
AU747883B2 (en) 1997-08-15 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
US6723319B1 (en) 1998-03-17 2004-04-20 Chugai Seiyaku Kabushiki Kaisha Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies
US8440196B1 (en) 1998-08-24 2013-05-14 Chugai Seiyaku Kabushiki Kaisha Treatment for pancreatitis using IL-6 receptor antagonist antibodies
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
WO2001027116A2 (en) 1999-10-07 2001-04-19 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
WO2002033073A1 (en) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
CN1259973C (zh) 2000-10-25 2006-06-21 中外制药株式会社 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
CN100374457C (zh) 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途
KR20110091822A (ko) 2002-02-14 2011-08-12 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
CN101371924A (zh) * 2003-04-09 2009-02-25 健泰科生物技术公司 治疗对tnf-alpha抑制剂应答不充分的患者中的自身免疫病
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
DE602005020743D1 (de) 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
WO2006046661A1 (ja) 2004-10-28 2006-05-04 Osaka University インターロイキン－６阻害剤
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
JP2009516692A (ja) 2005-11-22 2009-04-23 ワイス 免疫グロブリン融合タンパク質製剤
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ME00519B (me) * 2006-06-02 2011-10-10 Regeneron Pharma Antitijela visokog afiniteta prema humanom il-6 receptoru
EA200870538A1 (ru) 2006-06-14 2009-04-28 Имклоун Системз Инкорпорейтед Лиофилизированные композиции анти-egfr антител
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
JP2010507624A (ja) 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
JP2008189637A (ja) 2007-02-08 2008-08-21 Snow Brand Milk Prod Co Ltd 自己免疫疾患予防剤
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
HRP20160209T1 (hr) 2008-04-11 2016-03-25 Chugai Pharmaceutical Co Ltd Antigenski vežuća molekula koja se može višekratno vezati na dva ili više antigena
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2010225951B2 (en) 2009-03-19 2014-03-13 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20130053751A1 (en) 2011-08-31 2013-02-28 Frank Holtham Needle with an antiseptic swab
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US20150077582A1 (en) 2013-09-13 2015-03-19 Texas Instruments Incorporated Method and system for adapting a device for enhancement of images
CN120514847A (zh) 2013-11-22 2025-08-22 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法

Also Published As

Publication number Publication date
BR112014008764A2 (pt) 2017-06-13
MY177212A (en) 2020-09-09
TW201321017A (zh) 2013-06-01
KR20140123474A (ko) 2014-10-22
DK2766039T3 (en) 2018-03-05
MA35620B1 (fr) 2014-11-01
JP2018135373A (ja) 2018-08-30
JP2020143121A (ja) 2020-09-10
EP2766039A1 (en) 2014-08-20
MX388710B (es) 2025-03-20
AR088289A1 (es) 2014-05-21
EP2766039B1 (en) 2017-11-22
US10927435B2 (en) 2021-02-23
MX353126B (es) 2017-12-20
CN104105505A (zh) 2014-10-15
SG11201401373RA (en) 2014-05-29
ES2660112T3 (es) 2018-03-20
SG10201807042YA (en) 2018-09-27
JP2014530226A (ja) 2014-11-17
CL2014000926A1 (es) 2014-11-21
BR112014008764A8 (pt) 2017-09-12
RU2664697C2 (ru) 2018-08-21
HUE036561T2 (hu) 2018-07-30
CN108310376A (zh) 2018-07-24
AU2012323062B2 (en) 2017-08-31
WO2013053751A1 (en) 2013-04-18
JP2017137338A (ja) 2017-08-10
MX2021015309A (es) 2022-06-02
AU2012323062A1 (en) 2014-05-01
US20210230719A1 (en) 2021-07-29
JP6336171B2 (ja) 2018-06-06
CO6950482A2 (es) 2014-05-20
UY34387A (es) 2013-05-31
RS56973B1 (sr) 2018-05-31
JP7025477B2 (ja) 2022-02-24
SI2766039T1 (en) 2018-05-31
JP6122018B2 (ja) 2017-04-26
IL232001A0 (en) 2014-05-28
JP2024069453A (ja) 2024-05-21
PL2766039T3 (pl) 2018-06-29
SG10201607215SA (en) 2016-10-28
PH12014500784A1 (en) 2014-05-12
KR20220035272A (ko) 2022-03-21
CA2851751A1 (en) 2013-04-18
TWI589299B (zh) 2017-07-01
TR201802387T4 (tr) 2018-03-21
MX2014004398A (es) 2014-09-08
LT2766039T (lt) 2018-04-10
PT2766039T (pt) 2018-02-26
US20140302053A1 (en) 2014-10-09
PH12014500784B1 (en) 2019-10-16
JP6983717B2 (ja) 2021-12-17
KR20190014117A (ko) 2019-02-11
RU2014118741A (ru) 2015-11-20

Similar Documents

Publication Publication Date Title
BR112014017635A2 (en:Method)
BR112014017592A2 (en:Method)
NO2766039T3 (en:Method)
BR112014017607A2 (en:Method)
AR092201A1 (en:Method)
BR112014019011A2 (en:Method)
BR112013027865A2 (en:Method)
BR112014017609A2 (en:Method)
BR112014025444A2 (en:Method)
BR112014018324A2 (en:Method)
BR112014019245A2 (en:Method)
BR112014018485A2 (en:Method)
BR112014017588A2 (en:Method)
BR112014013184A8 (en:Method)
BR112014017630A2 (en:Method)
BR112014017627A2 (en:Method)
BR112014019730A2 (en:Method)
BR112014017621A2 (en:Method)
BR112014017631A2 (en:Method)
BR112014019948A2 (en:Method)
BR112014017589A2 (en:Method)
BR112014017671A2 (en:Method)
BR112014017636A2 (en:Method)
BR112014017667A2 (en:Method)
BR112014018204A2 (en:Method)